Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.

Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc ( ($ZNTL) ) has released its Q3 earnings. Here is a breakdown of the information Zentalis Pharmaceuticals Inc presente...

Zentalis Pharmaceuticals Reports Q3 2025 Financial Results

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Zentalis Pharmaceuticals today and set a price target of $10.00. Y. Maldonad...

Market Cap	$98.10M	P/E Ratio	N/A
52W High	$4.00	52W Low	$1.01
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	14.4%	52W Position	11.0%
Overall Score	39	Value Score	60
Quality Score	--	Technical Score	18

EPS Current Est	$-1.8	EPS Next Est	$-1.66
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZNTL	$1.34	+3.08%	388.90K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZNTL	$1.34	+3.1%	388.90K
3
4
5
6

ZNTL

ZNTL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Zentalis Pharmaceuticals Inc. Data in Excel

Get Zentalis Pharmaceuticals Inc. Data in Excel